Moreover, a recent meta-analysis outside of the co-mutation scope posited that SMARCA4-mutated class 1 was associated with worse OS for NSCLC patients (HR = 1.63; 95% CI: 1.44–1.85; p < 0.00001) in contrast to SMARCA4-mutated class 2 where no OS association was observed (HR = 1.34; 95% CI: 0.87–2.06; p = 0.18) [29]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.